FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1497466634> ?p ?o ?g. }

• W1497466634 endingPage "74" @default.
• W1497466634 startingPage "67" @default.
• W1497466634 abstract "Abstract Few activities in research garner more public notoriety than using human research subjects. Protecting human subjects is not the traditional fare of research administrators, but a knowledgeable administrator can catch pitfalls missed by the uninformed investigator. This article discusses clinical trials in general, protecting human research subjects, and the role the research administrator can play in facilitating the process. This discussion is not intended to be a thorough treatise on clinical trials or, for that matter, on any one subject relating to clinical trials. Rather it is an overview of new and lesser known human protection issues that are better handled prospectively. Introduction Today, there are few activities in research that garner more public notoriety (positive and negative) than using human research subjects. Protecting human subjects is not the traditional fare of research administrators, but a knowledgeable administrator can be of considerable assistance by alerting investigators to options to conduct better quality studies and avoid potential pitfalls that catch the uninformed investigator unaware. The early medical advances took place largely without public oversight. However, events of the last century when public awareness, world wars, complex scientific advances, and new emphasis on human rights issues have brought research involving humans under increased scrutiny. Since the 1940s numerous medical and governmental groups have met to better define the rules and ethics of human research. The Nuremberg Report, the Declaration of Helsinki, and the Belmont Report are the most often cited of these efforts. In the United States, the regulations governing oversight of federally funded clinical research and those leading to the licensing of pharmaceuticals, biologics, and medical devices have developed along different ideological pathways to achieve the same end. Research funded by the Department of Health and Human Services (HHS) or other federal agencies is governed by principles regulating the process by which the research is conducted; the Common Rule, by contrast, the Food and Drug Administration (FDA) regulates investigational products by controlling the conditions under which they are produced and used. It is important to note that neither set of regulations controls or limits the practice of medicine by qualified, licensed physicians using approved medications and devices within their clinical patient practice. State governments regulate that process. A latecomer to the human protections scene is the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceiiticals for Human Use (ICH). Manufacturers and regulators in the United States, Japan, and Europe signed this international treaty in 1991. The goal of the treaty was to establish uniform standards for conducting clinical drug trials to eliminate the need for research conducted in one country to be repeated in the others, thus reducing costs and exposing fewer individuals to the added research risks. The ICH guidelines are advisory, not regulatory in nature. Studies compliant with the ICH guidelines will also be compliant with both FDA and HHS regulations. For the purpose of this discussion, however, it is sufficient to note that all three systems rely on the Institutional Review Board (IRB), a group of scientists, non-scientists, and community representatives, to oversee research protections involving humans. The Institutional Review Board The Institutional Review Board (IRB) has, as its only mandate, protecting the rights and welfare of human subjects. This is accomplished through the initial and continuing review of the research protocols, adverse events, amendments, and other issues involving the study participants. Maintaining compliance is difficult given the volume of regulations, guidelines, policies, and ever increasing demands on the investigator's time. …" @default.
• W1497466634 created "2016-06-24" @default.
• W1497466634 creator A5059400710 @default.
• W1497466634 date "2002-01-01" @default.
• W1497466634 modified "2023-09-23" @default.
• W1497466634 title "Protection of Human Subjects: A Primer for the New Administrator." @default.
• W1497466634 hasPublicationYear "2002" @default.
• W1497466634 type Work @default.
• W1497466634 sameAs 1497466634 @default.
• W1497466634 citedByCount "1" @default.
• W1497466634 countsByYear W14974666342017 @default.
• W1497466634 crossrefType "journal-article" @default.
• W1497466634 hasAuthorship W1497466634A5059400710 @default.
• W1497466634 hasConcept C106977388 @default.
• W1497466634 hasConcept C142724271 @default.
• W1497466634 hasConcept C15744967 @default.
• W1497466634 hasConcept C169437150 @default.
• W1497466634 hasConcept C17744445 @default.
• W1497466634 hasConcept C188147891 @default.
• W1497466634 hasConcept C199539241 @default.
• W1497466634 hasConcept C204787440 @default.
• W1497466634 hasConcept C2775998707 @default.
• W1497466634 hasConcept C2776050585 @default.
• W1497466634 hasConcept C2992130261 @default.
• W1497466634 hasConcept C39549134 @default.
• W1497466634 hasConcept C535046627 @default.
• W1497466634 hasConcept C68122502 @default.
• W1497466634 hasConcept C71924100 @default.
• W1497466634 hasConceptScore W1497466634C106977388 @default.
• W1497466634 hasConceptScore W1497466634C142724271 @default.
• W1497466634 hasConceptScore W1497466634C15744967 @default.
• W1497466634 hasConceptScore W1497466634C169437150 @default.
• W1497466634 hasConceptScore W1497466634C17744445 @default.
• W1497466634 hasConceptScore W1497466634C188147891 @default.
• W1497466634 hasConceptScore W1497466634C199539241 @default.
• W1497466634 hasConceptScore W1497466634C204787440 @default.
• W1497466634 hasConceptScore W1497466634C2775998707 @default.
• W1497466634 hasConceptScore W1497466634C2776050585 @default.
• W1497466634 hasConceptScore W1497466634C2992130261 @default.
• W1497466634 hasConceptScore W1497466634C39549134 @default.
• W1497466634 hasConceptScore W1497466634C535046627 @default.
• W1497466634 hasConceptScore W1497466634C68122502 @default.
• W1497466634 hasConceptScore W1497466634C71924100 @default.
• W1497466634 hasIssue "2" @default.
• W1497466634 hasLocation W14974666341 @default.
• W1497466634 hasOpenAccess W1497466634 @default.
• W1497466634 hasPrimaryLocation W14974666341 @default.
• W1497466634 hasRelatedWork W1126148861 @default.
• W1497466634 hasRelatedWork W169152615 @default.
• W1497466634 hasRelatedWork W1903966615 @default.
• W1497466634 hasRelatedWork W2045625729 @default.
• W1497466634 hasRelatedWork W20731673 @default.
• W1497466634 hasRelatedWork W2076083446 @default.
• W1497466634 hasRelatedWork W2088904007 @default.
• W1497466634 hasRelatedWork W2091584710 @default.
• W1497466634 hasRelatedWork W2096901123 @default.
• W1497466634 hasRelatedWork W2100789740 @default.
• W1497466634 hasRelatedWork W2115095948 @default.
• W1497466634 hasRelatedWork W2137027232 @default.
• W1497466634 hasRelatedWork W2167686450 @default.
• W1497466634 hasRelatedWork W2416219923 @default.
• W1497466634 hasRelatedWork W2612634357 @default.
• W1497466634 hasRelatedWork W2741011940 @default.
• W1497466634 hasRelatedWork W2996728492 @default.
• W1497466634 hasRelatedWork W3125616967 @default.
• W1497466634 hasRelatedWork W338001133 @default.
• W1497466634 hasRelatedWork W2100841257 @default.
• W1497466634 hasVolume "33" @default.
• W1497466634 isParatext "false" @default.
• W1497466634 isRetracted "false" @default.
• W1497466634 magId "1497466634" @default.
• W1497466634 workType "article" @default.